Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Inclusion Criteria: * History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC. * Completely resected hepatic metastases without current evidence of other metastatic disease. * Lab values ≤ 14 days prior to treatment start: * WBC ≥ 3.0 K/uL * ANC \> 1.5 K/uL * Platelets ≥ 100,000/uL * Creatinine \<1.5 mg/dL * HGB ≥ 9 gm/dL Renal function (≤ 14 days prior to treatment start). * Creatinine ≤1.5 mg/dL or creatinine clearance ≥ 50 mL/min calculated by the Cockcroft-Gault method as follows: * Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl x 72) * Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy regimen) Hepatic function, as follows: (≤ 14 days prior to treatment start) * Aspartate aminotransferase (AST) (≤ 5 x ULN) * Alanine aminotransferase (ALT) (≤ 5 x ULN) * Total Bilirubin ≤ 1.5 mg/dl * Magnesium ≥ lower limit of normal (≤ 48 hours prior to treatment start.) * Calcium ≥ lower limit of normal (≤ 48 hours prior to treatment start.) * Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study. \[Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study.\] * Any investigational agent is acceptable i…